- Home
- ASND vs VTRS Comparison
ASND vs VTRS Comparison
Compare ASND & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- VTRS
- Stock Information
- Founded
- ASND 2006
- VTRS 1961
- Country
- ASND Denmark
- VTRS United States
- Employees
- ASND N/A
- VTRS N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- ASND Health Care
- VTRS Health Care
- Exchange
- ASND Nasdaq
- VTRS Nasdaq
- Market Cap
- ASND 10.6B
- VTRS 10.6B
- IPO Year
- ASND 2015
- VTRS N/A
- Fundamental
- Price
- ASND $170.86
- VTRS $8.93
- Analyst Decision
- ASND Strong Buy
- VTRS Hold
- Analyst Count
- ASND 16
- VTRS 5
- Target Price
- ASND $218.19
- VTRS $10.40
- AVG Volume (30 Days)
- ASND 435.4K
- VTRS 12.6M
- Earning Date
- ASND 05-01-2025
- VTRS 08-07-2025
- Dividend Yield
- ASND N/A
- VTRS 5.37%
- EPS Growth
- ASND N/A
- VTRS N/A
- EPS
- ASND N/A
- VTRS N/A
- Revenue
- ASND $398,509,511.00
- VTRS $14,330,200,000.00
- Revenue This Year
- ASND $75.05
- VTRS N/A
- Revenue Next Year
- ASND $78.14
- VTRS $1.85
- P/E Ratio
- ASND N/A
- VTRS N/A
- Revenue Growth
- ASND 12.06
- VTRS N/A
- 52 Week Low
- ASND $111.09
- VTRS $6.85
- 52 Week High
- ASND $183.00
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- ASND 52.37
- VTRS 53.22
- Support Level
- ASND $166.84
- VTRS $8.84
- Resistance Level
- ASND $180.78
- VTRS $9.16
- Average True Range (ATR)
- ASND 5.57
- VTRS 0.21
- MACD
- ASND -0.53
- VTRS 0.00
- Stochastic Oscillator
- ASND 38.59
- VTRS 50.94
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.